Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis
NCT07768254Phase 1Not yet recruiting
- Sponsor
- Helixon
- Start
- Sep 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of HX15001 in ulcerative colitis (UC) (3 arms), sponsored by Helixon. Primary endpoint: Adverse Events at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
HX15001
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07768254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768254.